Holen Sie sich die Stockscreener-App
1.10
3.51%
-0.04
Schlusskurs vom Vortag:
$1.14
Offen:
$1.1
24-Stunden-Volumen:
8,788
Relative Volume:
0.16
Marktkapitalisierung:
$11.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.98M
KGV:
-0.3855
EPS:
-2.8535
Netto-Cashflow:
$-14.55M
1W Leistung:
+0.00%
1M Leistung:
+12.41%
6M Leistung:
-37.85%
1J Leistung:
-45.36%
1-Tages-Spanne:
$1.09
$1.125
1-Wochen-Bereich:
$1.09
$1.22
52-Wochen-Spanne:
$0.88
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.1199 | 11.24M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
520.88 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.06 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.68 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.70 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - BioSpace
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - Stock Titan
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i - tradingview.com
2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - Stock Titan
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Valion Bio, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Valion Bio (VBIO) holder nears 10% after big preferred swap - Stock Titan
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
BRVE SEC FilingsBraveheart Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - tradingview.com
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss - Stock Titan
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - finance.yahoo.com
Large equity grants for TELA Bio, Inc. (TELA) CEO Heather Getz - Stock Titan
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
Heather Getz named CEO of TELA Bio as Antony Koblish exits - TradingView
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
Tevogen Inc. (NASDAQ: TVGN) changes name from Tevogen Bio Holdings - Stock Titan
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Tevogen Bio Holdings Inc. Becomes Tevogen Inc. - GlobeNewswire
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):